Business Wire

Comscore Adds CTV Measurement to Video Metrix® Multi-Platform in Five Key Markets in Europe

Share

Comscore (NASDAQ: SCOR), a trusted partner for planning, transacting, and evaluating media across platforms, today announced the addition of CTV measurement to its Video Metrix® Multi-Platform product, including YouTube traffic sharing measurement, for Spain and the UK. The report will also be included in June for Italy, and for France and Germany in July 2022. As a result, Comscore is the first international measurement provider to deliver complete audience measurement across YouTube’s largest platforms at the device level–PC, mobile and connected TV (CTV).

The expansion enables buy-side clients to leverage Comscore’s Video Metrix Multi-Platform solution to account for CTV viewing when forming YouTube strategy for key areas of content. This provides advertisers full-cycle enablement across planning and measurement of their YouTube investment. Furthermore, it offers content owners a holistic view of their CTV content, as well as their competitor’s content, allowing them to understand how engagement differs across platforms for better planning and monetization.

“As CTV continues to grow, it’s become critical to expand cross-platform measurement, particularly in international markets where similar CTV and OTT syndicated offerings do not currently exist,” said Joris Goossens, SVP Europe & APAC, Comscore. “With the addition of YouTube to our Video Metrix product, advertisers in European key markets will be able to perform true cross-platform evaluation, by understanding the true engagement metrics across all screens of their YouTube video investments and inform planning by selecting the best content categories and YouTube channels to execute their multi-platform campaigns.”

“We manage and produce video content for hundreds of brands across all social video platforms, YouTube being an important one, so it's crucial for us to have access to wide range of insights on video consumption, allowing us to better understand our audiences and improve our content and strategy,” said Graham Swallow, Head of Data, Tech and Product at Little Dot Studios.

Comscore Video Metrix Multi-Platform delivers a total view of consumer video consumption across desktops, smartphones, tablets, and CTV devices. Premium video content and advertising can be strategically planned, bought, and sold across platforms using digital-exclusive metrics.

Over the next several months, Video Metrix Multi-Platform CTV measurement will continue to expand into additional markets across Asia, and Latin America.

About Comscore

Comscore (NASDAQ: SCOR) is a trusted partner for planning, transacting and evaluating media across platforms. With a data footprint that combines digital, linear TV, over-the-top and theatrical viewership intelligence with advanced audience insights, Comscore allows media buyers and sellers to quantify their multiscreen behavior and make business decisions with confidence. A proven leader in measuring digital and TV audiences and advertising at scale, Comscore is the industry’s emerging, third-party source for reliable and comprehensive cross-platform measurement. To learn more about Comscore, visit www.comscore.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Bill Daddi
bill@daddibrand.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

A-CAP Announces Successful Divestiture of Standard de Liège SA and Immobilière du Standard de Liège SRL6.6.2025 23:32:00 EEST | Press release

Advantage Capital Holdings, LLC (“A-CAP” or “The Company”), a New York-based insurance and financial services company with over $12 billion in assets, today announced the successful divestiture of Standard de Liège SA (“Standard Liège” or the “Club”), one of Belgium's most historic soccer clubs, and Immobilière du Standard de Liège SRL, the corporate entity that owns the Club's stadium, Maurice Dufrasne Stadium, to a consortium of buyers led by Standard Liège Chief Executive Officer Giacomo Angelini. This transaction marks the end of 777 Partners’ legacy involvement with the Club and sets the stage for the Club’s future growth and success, both on and off the field. Benefits of the transaction include: Increased stability across the Club’s shareholder base, which clears the path for future investments, Operational clarity, establishing a unified direction that will allow both players and management to fully concentrate on on-field performance, ensuring that collective focus remains on

Populous Acquires Fentress Architects, Expanding Global Aviation Portfolio6.6.2025 21:00:00 EEST | Press release

Populous, the world-renowned design firm specializing in sport and entertainment venues, today announced the acquisition of Denver-based Fentress Architects, a global leader in iconic aviation projects and prominent public buildings, including convention centers, museums and government facilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606849000/en/ Los Angeles International Airport. Designed by Fentress Architects. This strategic acquisition unites two of the most respected names in architecture, combining Populous’ unparalleled expertise in designing memorable experiences with Fentress’ award-winning portfolio of aviation, civic and cultural landmarks. The acquisition significantly broadens the scope and scale of services that Populous can offer clients across the globe. Bruce Miller, Populous Global Chair and CEO, commented: “We are committed to expanding the breadth of our practice. Fentress Architects has lon

Vertex Presents New Data on Benefits of ALYFTREK ® and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference6.6.2025 19:00:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data across multiple studies demonstrating positive clinical and quality of life benefits of treatment with CFTR modulators and, in particular, ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor), which is approved in the United States and United Kingdom and is currently under review with health authorities in the EU, Canada, Australia, New Zealand and Switzerland. These data were presented at this year’s European Cystic Fibrosis Society’s (ECFS) 48th European Cystic Fibrosis Conference held June 4-7, 2025, in Milan, Italy. During the conference, the Company presented data from a pooled analysis across CFTR modulators, including ALYFTREK, which demonstrate that reduction in sweat chloride (SwCl), and therefore greater restoration of CFTR function, is associated with improved outcomes in people with cystic fibrosis (CF). For all clinical outcomes in the study, SwCl levels below 60 mmol/L were associated with greater benefit

IBSA Derma at IMCAS Asia 2025: spotlight on the future of aesthetic medicine in the 10 th Anniversary Year of NAHYCO ® Technology6.6.2025 17:00:00 EEST | Press release

IBSA Derma – the dermoaesthetic division of IBSA – once again confirms its leadership in the international aesthetic medicine landscape by participating in the 18th edition of IMCAS Asia, taking place from June 6 to 8 in Bangkok, Thailand. With over 3,000 attendees expected, the event represents a key opportunity for physicians and experts to share the latest innovations and cutting-edge advancements in aesthetic procedures and treatments, staying at the forefront of this dynamic field. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250603094257/en/ IBSA’s stand at IMCAS Asia 2025 As part of the congress, IBSA Derma will host a scientific symposium titled “The Future of Tissue Regeneration with NAHYCO® Technology. Feeling and Seeing the Results with Profhilo® Line” scheduled for Saturday, June 7, from 3:00 to 4:00 pm ICT in Room 1 - Level 2. Internationally renowned speakers – Dr. Lam Bee Lan and Prof. Ofir Artzi – will lead

HistoSonics Completes Enrollment in #HOPE4KIDNEY Trial Evaluating Non-Invasive Histotripsy to Treat Kidney Tumors6.6.2025 15:00:00 EEST | Press release

HistoSonics, Inc., the manufacturer of the Edison® Histotripsy System and novel histotripsy therapy platforms, today announced the completion of patient enrollment in its pivotal #HOPE4KIDNEY trial. This prospective, multi-center, single-arm trial is designed to evaluate the safety and effectiveness of the Edison System in destroying kidney tissue by treating primary solid kidney tumors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606659747/en/ Edison Histotripsy System Procedure for Kidney Tumor Animation The trial enrolled patients with a single, non-metastatic solid kidney mass ≤3 cm, confirmed by imaging and biopsy. Subjects will be followed for five years post-procedure, with evaluations at multiple time points, including 14-day, 30-day, 90-day, 180-day, and annual assessments. The Edison System remains in investigational use for kidney applications and is not yet FDA-approved for this indication. Data from the #H

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye